Clinical Trials Browser

Phase 1/2 × INDUSTRY × Natalizumab × Clear all

NCT00675428 2014-09-19

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

6 enrolled 6 charts

Multiple Myeloma, Recurrence